Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Chan JSK. Aspirin-omitted dual antithrombotics vs. triple antithrombotics: a trial sequential analysis. Eur Heart J Cardiovasc Pharmacother 2020;7:e32-e34. [PMID: 32484857 DOI: 10.1093/ehjcvp/pvaa061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]

For:	Chan JSK. Aspirin-omitted dual antithrombotics vs. triple antithrombotics: a trial sequential analysis. Eur Heart J Cardiovasc Pharmacother 2020;7:e32-e34. [PMID: 32484857 DOI: 10.1093/ehjcvp/pvaa061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]

Number	Cited by Other Article(s)
1	Agewall S. New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials. EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY 2022;8:213-215. [PMID: 35435962 DOI: 10.1093/ehjcvp/pvac019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 03/16/2022] [Indexed: 06/14/2023] Abstract Collapse Key Words Collapse MESH Headings Atrial Fibrillation/diagnosis Atrial Fibrillation/drug therapy Atrial Fibrillation/epidemiology Cardiology Cholesterol Diabetes Mellitus/drug therapy Fabry Disease/complications Fabry Disease/drug therapy Fibrinolytic Agents/adverse effects Gout/complications Gout/drug therapy Humans Insulin/therapeutic use Male Myocardial Infarction/drug therapy Out-of-Hospital Cardiac Arrest/drug therapy Prostatic Neoplasms/complications Prostatic Neoplasms/diagnosis Prostatic Neoplasms/drug therapy Risk Factors Sodium-Glucose Transporter 2 Inhibitors/therapeutic use Stroke Volume Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Agewall S. New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials. EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY 2022;8:213-215. [PMID: 35435962 DOI: 10.1093/ehjcvp/pvac019] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 03/16/2022] [Indexed: 06/14/2023]